Active Ingredient History
Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Colitis, Ulcerative (approved 2020)
Multiple Sclerosis (approved 2020)
Carcinoma, Hepatocellular (Phase 2)
Colitis, Ulcerative (Phase 4)
COVID-19 (Phase 2)
Crohn Disease (Phase 3)
Digestive System Diseases (Phase 1)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 1)
Liver Diseases (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Multiple Sclerosis (Phase 4)
Neoplasms (Phase 1/Phase 2)
Psoriasis (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue